FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Clears GE Critical Care Suite 2.1

[ Price : $8.95]

FDA clears GE Healthcares Critical Care Suite 2.1 that includes a pneumothorax algorithm.

Arcturus Therapeutics Orphan Status for ARCT-032

[ Price : $8.95]

FDA grants Arcturus Therapeutics an orphan drug designation for ARCT-032 and its use to treat cystic fibrosis.

Regulatory Review Determinations on 8 NDAs

[ Price : $8.95]

Federal Register notices: FDA publishes notices about the regulatory review period determinations for eight drug products sponsore...

Karuna NDA for Schizophrenia Accepted by FDA

[ Price : $8.95]

FDA accepts for review a Karuna Therapeutics NDA for KarXT (xanomeline-trospium) for treating schizophrenia in adults.

Praise for Graft-Versus-Host Drug Guidance

[ Price : $8.95]

Stakeholders comment positively on an FDA draft guidance on developing products to prevent or treat graft-versus-host disease.

FDA Studies Nasal Spray Distribution

[ Price : $8.95]

A CDER study examines generic nasal spray distribution factors that could speed the development of generic sprays.

Vivos Sleep Apnea Device Cleared

[ Price : $8.95]

FDA clears a Vivos Therapeutics 510(k) for its Vivos CARE (Complete Airway Repositioning and/or Expansion) appliances for treating...

FDA Still Evaluating Left Atrial Occlusion Implants

[ Price : $8.95]

FDA continues to evaluate information about the potential for differences in procedural outcomes between women and men undergoing ...

New Theories of False Claims Act Liability

[ Price : $8.95]

A lengthy online newsletter written by several Skadden attorneys explores possible new theories of cybersecurity False Claims Act ...

AdvaMed Comments on Electronic Submission Guide

[ Price : $8.95]

AdvaMed raises concerns about an FDA draft guidance on De Novo electronic submissions.